Table 1.
Clinical Characteristics of 564 Patients With AHF in Quartiles of miR‐19b‐3p Levels
|
Overall (N=564) |
Q1 (N=141) |
Q2 (N=141) |
Q3 (N=141) |
Q4 (N=141) |
P value | |
|---|---|---|---|---|---|---|
| Age, y | 69.0 (62.0, 77.0) | 70.0 (63.0, 82.0) | 68.0 (61.0, 77.0) | 69.0 (62.0, 75.0) | 70.0 (61.0, 78.0) | 0.214 |
| Male/female, n/n | 404/160 | 99/42 | 99/42 | 101/40 | 105/36 | 0.790 |
| BMI, kg/m2 | 24.3±3.6 | 24.3±3.6 | 24.0±3.8 | 24.5±3.6 | 24.5±3.6 | 0.950 |
| Smoking, n (%) | 175 (31.0) | 47 (33.3) | 43 (30.5) | 49 (34.8) | 36 (25.5) | 0.456 |
| NYHA functional class | 2.4±0.8 | 2.4±0.8 | 2.4±0.7 | 2.3±0.8 | 2.5±0.8 | 0.080 |
| HR, bpm | 83.7±18.5 | 83.9±18.7 | 84.1±17.9 | 83.7±18.6 | 82.9±19.0 | 0.977 |
| SBP, mm Hg | 135.5±23.7 | 137.1±23.3 | 133.6±23.4 | 134.5±24.5 | 137.0±23.7 | 0.900 |
| DBP, mm Hg | 79.2±15.8 | 79.6±15.5 | 78.9±15.6 | 78.7±15.5 | 79.4±16.6 | 0.847 |
| Comorbidities | ||||||
| Diabetes, n (%) | 205 (36.4) | 45 (31.9) | 50 (35.5) | 53 (37.6) | 57 (40.4) | 0.463 |
| Hypertension, n (%) | 373 (66.1) | 95 (67.4) | 81 (57.4) | 93 (66.0) | 104 (73.8) | 0.024* |
| CHD, n (%) | 344 (61.0) | 82 (58.2) | 85 (60.3) | 89 (63.1) | 88 (62.4) | 0.657 |
| AF, n (%) | 118 (20.9) | 37 (26.2) | 24 (17.0) | 31 (22.0) | 26 (18.4) | 0.205 |
| ICM, n (%) | 123 (21.8) | 30 (21.3) | 30 (21.3) | 34 (24.1) | 29 (20.6) | 0.893 |
| HCM, n (%) | 8 (1.4) | 2 (1.4) | 1 (0.7) | 2 (1.4) | 3 (2.1) | 0.798 |
| DCM, n (%) | 31 (5.5) | 10 (7.1) | 4 (2.8) | 8 (5.7) | 9 (6.4) | 0.418 |
| Serological measurements | ||||||
| NT‐proBNP, ng/mL | 1918.0 (782.5, 5070.5) | 2170.0 (993.7, 4748.0) | 1960.0 (800.6, 5051.3) | 1986.0 (609.0, 6771.0) | 1636.0 (871.9, 4723.0) | 0.261 |
| vmiR‐19b‐3p (relative expression) | 2.15 (1.63, 3.40) | 1.23 (0.99, 1.43) | 1.89 (1.75, 2.00) | 2.69 (2.36, 2.96) | 5.24 (4.28, 6.73) | <0.001* |
| sST2, ng/mL | 42.3 (36.8, 50.7) | 38.4 (33.0, 42.4) | 40.6 (35.4, 47.2) | 42.6 (48.4, 38.5) | 53.4 (44.9, 67.4) | <0.001* |
| HDL, mmol/L | 0.96 (0.79, 1.20) | 1.02 (0.81, 1.31) | 0.98 (0.81, 1.25) | 0.93 (0.79, 1.13) | 0.94 (0.78, 1.15) | 0.521 |
| LDL, mmol/L | 2.16±0.93 | 2.07±0.91 | 2.15±0.98 | 2.24±0.94 | 2.19±0.88 | 0.627 |
| eGFR, mL/(min*1.73 m2) | 79.2 (56.4, 99.3) | 82.1 (64.2, 101.7) | 81.4 (55.5, 102.9) | 79.2 (57.8, 98.0) | 73.6 (54.9, 95.7) | 0.355 |
| BUN, mmol/L | 8.3±6.0 | 7.7±3.9 | 8.4±4.5 | 8.7±9.3 | 8.5±4.9 | 0.361 |
| Hb1Ac (%) | 6.3 (5.8, 7.4) | 6.4 (5.8, 7.3) | 6.3 (5.8, 7.5) | 6.2 (5.7. 7.0) | 6.3 (5.8, 7.5) | 0.678 |
| Echocardiographic measurements | ||||||
| LVEF (%) | 43.0 (32.0, 55.0) | 44.0 (33.0, 55.0) | 43.0 (30.0, 55.0) | 44.0 (35.8, 56.0) | 40.0 (32.3, 54.8) | 0.675 |
| IVST, mm | 10.0 (9.0, 11.0) | 9.0 (9.0, 10.0) | 9.0 (9.0, 10.0) | 10.0 (9.0, 10.0) | 11.0 (10.0, 13.0) | <0.001* |
| LVPWT, mm | 10.0 (9.0, 10.0) | 10.0 (9.0, 10.0) | 10.0 (9.0, 10.0) | 10.0 (9.0, 10.0) | 10.0 (9.0, 11.0) | 0.001* |
| LVeDD, mm | 50.0 (45.0 57.0) | 49.0 (44.0, 56.0) | 50.0 (44.0, 57.0) | 49.0 (45.0, 56.0) | 51.0 (45.0, 60.0) | 0.151 |
| LVeSD, mm | 35.5 (30.0, 46.0) | 32.0 (29.0, 43.0) | 31.0 (27.0, 45.0) | 34.0 (28.0, 44.0) | 37.0 (30.0, 47.0) | 0.241 |
| LVMI, g/m2 | 113.5±34.8 | 101.0±28.1 | 103.8±25.2 | 110.2±26.8 | 141.1±42.2 | <0.001* |
Continuous variables are presented as means±SD if conform normal distribution or median with interquartile range (IQR) if not. Categorical variables are presented as percentage (%). AF indicates atrial fibrillation; AHF, acute heart failure; BMI, body mass index; BUN, blood urea nitrogen; CHD, coronary heart disease; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; eGFR, estimated glomerular filtration rate (calculated by MDRD formula); Hb1Ac, hemoglobin A1c; HCM, hypertrophic cardiomyopathy; HDL, high‐density lipoprotein; HR, heart rate; ICM, ischemic cardiomyopathy; IVST, interventricular septum thickness; LDL, low‐density lipoprotein; LVeDD, left ventricular end‐diastolic diameter; LVEF, left‐ventricular ejection fraction; LVeSD, left ventricular end‐systolic diameter; LVMI, left ventricular mass index; LVPWT, left ventricular posterior wall thickness; NT‐proBNP, N‐terminal brain natriuretic peptide precursor; NYHA, New York Heart Association; SBP, systolic blood pressure; and sST2, soluble suppression of tumorigenicity 2.
Significant P value (<0.05).